суббота, 16 апреля 2016 г.

PTC Jumps Most Since 2014 as U.K. Regulator Recommends DMD Drug

PTC Jumps Most Since 2014 as U.K. Regulator Recommends DMD Drug


PTC Therapeutics Inc. soared the most since May 2014 after the U.K.'s health-cost regulator recommended its drug for a deadly muscle disease. The U.K.'s National Institute for Health and Care Excellence, known as NICE, recommended PTC's drug Translarna for some patients with Duchenne muscular dystrophy in England, according to a statement Friday.



from Biotech News